<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163185</url>
  </required_header>
  <id_info>
    <org_study_id>AXS-07-303</org_study_id>
    <nct_id>NCT04163185</nct_id>
  </id_info>
  <brief_title>Initiating Early Control of Migraine Pain and Associated Symptoms</brief_title>
  <acronym>INTERCEPT</acronym>
  <official_title>A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axsome Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axsome Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan,
      which is being developed for the acute treatment of migraine with or without aura in adults.
      AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This
      study is designed to evaluate the efficacy and safety of AXS-07 compared to placebo.

      This is a randomized, double-blind, single-dose, placebo-controlled trial. Subjects who
      successfully complete the screening period and continue to meet all entry criteria will be
      randomly assigned to take one dose of either AXS-07 or placebo upon the earliest onset of
      migraine pain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects reporting headache pain freedom</measure>
    <time_frame>Hour 2</time_frame>
    <description>Absence of headache pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with absence of Most Bothersome Symptom</measure>
    <time_frame>Hour 2</time_frame>
    <description>Absence of Most Bothersome Symptom, defined at the onset of migraine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>AXS-07</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taken once upon migraine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Taken once upon migraine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXS-07 (MoSEIC meloxicam and rizatriptan)</intervention_name>
    <description>AXS-07 tablet taken once upon the earliest onset of migraine pain.</description>
    <arm_group_label>AXS-07</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet taken once upon the earliest onset of migraine pain.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        â€¢ Has an established diagnosis of migraine with or without aura.

        Key Exclusion Criteria:

          -  Has previously received any investigational drug or device or investigational therapy
             within 30 days before Screening.

          -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>+1 (212) 332-3241</phone>
    <email>ajones@axsome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Study Coordinator</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>INTERCEPT Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://axsome.com</url>
    <description>Axsome Website</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>AXS-07</keyword>
  <keyword>Meloxicam</keyword>
  <keyword>Rizatriptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

